Guardant Health, Inc. (GH) は上場企業です ヘルスケア セクターの Medical - Diagnostics & Research 業界で事業展開. 本社所在地は Palo Alto, CA, アメリカ. 現CEOは Helmy Eltoukhy.
GH を有する IPO日 2018-10-04, 1,999 名の正社員, に上場 NASDAQ Global Select, 時価総額 $11.33B.
Guardant Health, Inc. is a precision oncology company that develops and provides innovative blood-based liquid biopsy tests and analytics for cancer detection and treatment. The company offers a portfolio of products including Guardant360 and its variants for advanced-stage cancer patients, GuardantINFORM for clinical genomic research, and LUNAR-2 for early colorectal cancer detection, as well as GuardantConnect, a software platform connecting patients with relevant clinical trials. Additionally, Guardant Health provides development services to biopharmaceutical companies and medical institutions, including companion diagnostic development, clinical trial support, and testing solutions. Headquartered in Redwood City, California, the company operates globally and serves the oncology market through its comprehensive suite of diagnostic and data analytics offerings.
